EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.
EASD 2021 HbA1c, body weight and SBP were lowered by semaglutide and liraglutide, regardless of background SGLT2i therapy in diabetes patients, in a post hoc analysis of SUSTAIN 6.
The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.
Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.
ESC 2021 Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.
ESC 2021 After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.
ESC 2021 In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.
ESC 2021 Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.
ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.
ESC 2021 Prof. de Boer gives an overview of the journey of SGLT2 inhibitors throughout the last years, from anti-diabetes drugs to demonstrated effectiveness in HFpEF.
ESC 2021 The EMPEROR-Preserved trial showed that empagliflozin significantly reduced the risk of the primary composite endpoint of CV death or HF hospitalization by 21%, compared to placebo, in patients with HF and LVEF >40%, with and without T2DM.